Evidence map›Paper›PMID 42318151›Full record

ArticleFrontiers in cardiovascular medicine2026

Immune checkpoint inhibitor-related myocarditis in a patient with hepatocellular carcinoma: a case report.

Yuqiang Zhou, Zhiliang Zhang, Shasha Liu, Jiang Nan, Zhuoli Zhang, Zixian Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuqiang Zhou *The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Zhiliang Zhang *The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Shasha LiuDepartment of Pathology, The First Hospital of Lanzhou University, Lanzhou, China.
Jiang NanDepartment of Radiology, The First Hospital of Lanzhou University, Lanzhou, China.
Zhuoli ZhangDepartments of Radiological Sciences, University of California, Irvine, CA, United States.
Zixian ChenDepartment of Radiology, The First Hospital of Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are pivotal in treating advanced malignancies, including hepatocellular carcinoma (HCC). However, they can trigger immune-related adverse events (irAEs), among which myocarditis is one of the most life-threatening. Herein, we report the case of a 56-year-old man with HCC who developed myocarditis after receiving two cycles of the PD-1 inhibitor sintilimab. The diagnosis was established via cardiac magnetic resonance (CMR) and confirmed by endomyocardial biopsy (EMB). Following treatment with high-dose corticosteroids and supportive therapy, the patient's condition exhibited significant improvement.

Indexed as

cardiac magnetic resonanceendomyocardial biopsyhepatocellular carcinomaimmune checkpoint inhibitorsimmune-related adverse eventsmyocarditis

Identifiers

PMID42318151
PMCPMC13272056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.